
Precision Medicine in Oncology®
Latest News
Advertisement
Latest Videos

Advertisement
More News








Amid an explosion of innovation and discovery in the oncology field, researchers are finding it increasingly difficult to recruit enough patients for clinical trials.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations.
















Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
3
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5












































































